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PENILAIAN FAKTOR RAMALAN DAN KADAR KELANGSUNGAN HIDUP 
PADA PESAKIT DENGAN PENYAKIT TULANG METASTATIK 
ABSTRAK 
PENGENALAN 
 Pengurusan penyakit tulang metastatik masih mencabar, bersama-sama 
dengan peningkatan dalam menguruskan tumor pepejal utama, pesakit hidup lebih 
lama dan mereka berpotensi untuk mendapat metastatik kepada tulang lebih daripada 
mereka ada sebelum ini. Pelbagai pilihan rawatan mungkin boleh diberi kepada 
pesakit termasuk rawatan perubatan, radiasi, kemoterapi dan pembedahan. 
Pembedahan untuk penyakit tulang metastatik memberikan keputusan yang 
memuaskan, bagaimanapun terdapat beberapa faktor yang mempengaruhi 
kelangsungan hidup pesakit yang mempunyai penyakit tulang metastatik seperti 
status prestasi, jenis tumor utama, defisit neurologi, tulang patologi, metastasis 
kepada organ viseral dan akhir sekali adalah kemoterapi. Oleh itu kajian ini 
dijalankan untuk menilai faktor-faktor ramalan yang  menjejaskan kelangsungan 
hidup dan kualiti hidup pesakit. 
KAEDAH 
  Seramai 40 pesakit yang mempunyai penyakit tulang metastatik dirawat 
segara pembedahan antara tahun 2008 sehingga tahun 2015 di unit onkologi 
ortopedik, Hospital Universiti Sains Malaysia, mereka telah dinilai secara 
retrospektif untuk menilai faktor-faktor ramalan yang  menjejaskan kelangsungan 
hidup, manakala borang soal selidik status prestasi ECOG (Eastern Cooperative 
Oncology Group) telah digunakan untuk menilai kualiti hidup pesakit pada tiga, 
enam dan dua belas bulan selepas pembedahan. Selepas itu, kelangsungan hidup 
dianalisis dengan kaedah Kaplan- Meier. 
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KEPUTUSAN 
  Terdapat 29 wanita dan 11 lelaki, tumor utama yang paling kerap adalah 
kanser payudara dengan 42.5%, diikuti oleh kanser tiroid 17.5%. pesakit selamat14 
(37.8%), manakala 23 (62,16%) pesakit meninggal dunia, dan kelangsungan hidup 
pertangahan ialah 36 bulan. Min umur pada adalah 54,43 tahun, terdapat 30% 
(12/40) melebihi 60 tahun dan 70% (28/40) di bawah 60 tahun, berdasarkan 
kumpulan umur, kadar kelangsungan hidup adalah  ketara secara statistik dengan 
nilai p (0.028). Faktor-faktor ramalan lain adalah termasuk kemoterapi dan lokasi 
metastasis tulang (appendicular, tulang paksi atau kedua-duanya) juga didapati 
mempunyai hubungan yang signifikan dengan nilai hidup p (0.003, 0.021) masing-
masing. Jenis pembedahan juga dilihat sebagai faktor penting yang berkaitan dengan 
kadar kelangsungan hidup (p nilai 0,038), pembedahan reseksi dan endoprosthesis 
adalah prosedur yang kerap dilakukan di pusat kami untuk (pinggul, tulang paha 
proksimal, bahu dan kecederaan sekitar sendi lutut) 58.97% (n = 24), diikuti oleh 
prosedur Harrington untuk pelvik yang merupakan 17.95%. 
Status prestasi ECOG (0-2) dan ECOG (3-5) pesakit telah dinilai dan didapati 
signifikan secara statistik sebagai faktor ramalan untuk kelangsungan hidup dalam 
kedua-dua kumpulan selepas tiga bulan, enam bulan dan dua belas bulan 
pembedahan. 
KESIMPULAN Kesimpulannya faktor ramalan yang  memberi kesan siginfikan 
kepada kelangsungan hidup pesakit dengan penyakit metastasis tulang adalah umur 
kurang daripada 60, lokasi kecederaan tulang, rawatan kemoterapi sebelumnya, dan 
jenis prosedur pembedahan yang dilakukan. Tambahan lagi kajian ini menunjukkan 
bahawa kualiti hidup adalah signifikan secara statistik berhubung dengan jenis 
pembedahan dan kelangsungan hidup secara keseluruhannya 
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EVALUATION OF PROGNOSTIC FACTORS AND SURVIVAL OF 
PATIENTS WITH METASTATIC BONE DISEASE 
 
ABSTRACT 
INTRODUCTION 
   Management of metastatic bone disease is still challenging, along with the 
improvement in managing primary solid tumors, patients survive longer and they 
become potential to have metastatic lesions of bone more than they had before. A 
variety of treatment options could possibly be given to those patients includes 
medical treatment, radiation, chemotherapy and surgical intervention. The surgical 
intervention for metastatic bone lesions gives satisfactory outcome. However, there 
are few factors affecting the survival of patients with metastatic bone disease such as 
performance status, type of primary tumor, neurology deficit, pathologic fracture, 
visceral organ metastasis and chemotherapy administration. This study was 
conducted to evaluate the prognostic factors affecting the median survival and 
patient’s‎quality‎of‎life. 
METHODS 
  A total of 40 patients with metastatic bone disease treated surgically between 
2008 to 2015 at orthopedics oncology unit, Hospital Universiti Sains Malaysia were 
evaluated retrospectively, for survival prognostic factors, while the performance 
status questionnaire of ECOG (Eastern Cooperative Oncology Group) was used to 
assess‎ the‎patient’s‎quality‎of‎ life‎ at‎ three,‎ six‎ and‎ twelve‎month‎after‎ the‎ surgery.‎
Subsequently, survival rate was analyzed by the Kaplan-Meier method.  
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RESULTS 
  There were 29 female and 11 male, the most common primary tumor was 
breast cancer with 42.5%, followed by thyroid cancer 17.5%. Over all  14 (37.8%) 
patients survived, while 23(62.16%) patients died, and the median survival was 36 
months. Mean age at presentation was 54.43 years, and there were 30% (12/40) 
above 60 years and 70% (28/40) below 60 years. Based on the age groups, the 
survival rate was statistically significant p value (0.028). Other prognostic factors 
include chemotherapy administration and site of bone metastasis (appendicular, axial 
bone or both together) were also significantly correlated with the survival p value of 
(0.003, 0.021), respectively. Types of the surgery was a significant factor associated 
with the survival (p-value 0.038), resection and endoprosthesis surgery was the most 
procedure performed in our center for (hip, proximal femur, shoulder  and around 
knee joint lesions) 58.97% (n=24), followed by Harrington procedure for pelvic 
involvement which was 17.95% . Performance status ECG (0-2) and ECOG (3-5) of 
patients was evaluated and found to be statistically significant as a prognostic factor 
for survival. 
CONCLUSION 
   In conclusion, the prognostic factors that significantly affect the survival of 
patient with bone metastasis were age which was less than 60, location of bone 
lesions, previous chemotherapy, and the type of performed surgical procedure. 
Additionally, the study revealed that the quality of life significantly correlated with 
the types of surgery and overall survival. Furthermore, the performance status 
(ECOG) significantly correlated with the types of surgery and age. 
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CHAPTER 1 
INTRODUCTION 
1.1  Cancer and bone metastases in Malaysia  
In Malaysia, a total of 18,219 new cancer cases in 2007 were diagnosed and 
registered at the National Cancer Registry. It comprises of 8,123 (44.6%) males and 
10,096 (55.4%) females. The most common cancers among population of Malaysia 
is breast (18.1%) followed by colorectal (12.3%), lung (10.2%), nasopharynx (5.2%), 
cervix (4.6%), lymphoma (4.3), leukaemia (4.1), ovary (3.6), stomach (3.5) and liver 
(Kachnic et al.). This was reported by (Adler and Gill) in Malaysia reports in 2007  
(Figure 1:1). 
Staging was reported for 8,869 from 18,219 (48.7%), stage I was found to be 17.0%, 
whereas 25.3% stage II, stage III and stage IV 25.0%, 32.7% respectively . 
Therefore, at the time of diagnosis, 57.6% were already at advance stages of cancer 
(Lim and Azura, 2008). 
 
Breast  cancer was the most common cancer in females and it was the most 
common cancer among population regardless of sex in Malaysia, Colorectal cancer 
was the second most common cancer after breast cancer and second most common 
cancer in males and females in Malaysia. Lung cancer is the most common cancer 
among males and third most common cancer in the general population.  
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Figure ‎1:1  The prevalence of the most common cancers reported among Malaysian 
population regardless of age sex and race, reported in Malaysian (NCR) 2007. 
There were 502 new prostate cancer cases diagnosed in 2007 which was 
reported in NCR, with prostate cancer considered the fourth most common cancer in 
Malaysia among males. The incidence of prostate cancer increases after the age of 45 
years and higher in Chinese males followed by Malay and Indian.  
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1.2  Metastatic bone disease  
Metastases to Bone from carcinomas are considered a medical, social and 
economic issue. About one-half of all primary cancers tend to disseminate to the 
bone, which is the third most frequent site of metastatic spread after the lung and the 
liver. Epidemiological investigation has shown that of 1.2 million new cases of 
cancer each year in the USA, in which about 300 000 will eventually develop a bone 
metastasis (Hage et al., 2000). Tumors which have a predilection to dissemination to 
the bone are prostate (32%), breast (22%) and kidney (16%) followed by the lung 
and the thyroid, the spine, pelvis, ribs, skull and proximal long bones; those are the 
sites most commonly involved (Bauer, 2005; Toma et al., 2007). In metastatic bone 
disease, six month survival rates have been reported in patients with primary solid 
tumor  prostate cancer, breast cancer, lung cancer and  kidney (98% ,89% ,50% 51%) 
respectively. 
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1.3  Justification of the study  
1.3.1 Morbidities caused by Metastasis to the Bone 
 
Most patients with metastatic bone disease have severe bone pain and debility. 
Moreover, they are sometimes bed bounded due to pain. Bone pain is frequently the 
first sign of metastatic disease and approximately 80% of all breast cancer patients 
will have one episode of bone pain that requires treatment. A major cause of 
prolonged disability is pathologic fracture (eg, rib fracture, long bone fracture and 
vertebral collapse), which is the second most common complication of bone 
metastases, occurring in 10% to 20% of patients. Hypercalcemia of malignancy 
developed in approximately 10% to 15% of patients; where elevated serum calcium 
levels from bone destruction can lead to gastrointestinal, renal, and central nervous 
system dysfunction. Spinal cord compression occurs in up to 5% of patients with 
metastatic bone disease (Coleman et al., 2010). 
 
Skeletal-related events (SRE) cause significant morbidity reduced 
performance status, quality of life (QOL), poor functional capacity and reduced 
survival.  
The economic consequences of metastatic bone disease are substantial. In a 
retrospective analysis of breast cancer patients with bone metastases, the cost of 
treating skeletal complications was approximately $52,000 and more in patients with 
skeletal-related events than in patients without these events. There is also an 
estimated cost of 1.9 billion dollars every year in  the United States, cost of treatment 
of a single SRE episode per patient varying from USD 6,973 to 11,979 (Jayasekera et 
al., 2014). 
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Despite of various studies being done on prognostic factors of metastatic 
bone disease, no concrete conclusions at this time available. 
The effect of surgical treatment on the function and the survival of 
patients with metastatic bone disease 
 
Metastatic bone lesions do not always require surgical intervention; factors 
influencing the decision include size, location of the particular lesion, general 
medical status and expected survival of the patient. A small metastatic lesion that 
affects <50% of the cortex or a lesion in a non-weight-bearing bone (e.g. fibula bone) 
may not require surgical intervention, patients with severe medical comorbidities or a 
short expected remaining survival time may not be good candidates for surgical 
intervention, and some lytic lesions in the extremities were not at risk for 
pathological fracture might be treated with radiation and medications. 
However, non-operative management is rarely utilized for pathologic 
fractures in the lower extremity due to metastatic bone lesion, but in certain cases 
such as patients with severe comorbidities such as cardiopulmonary disease or 
widespread metastasis with a short expected remaining life span (less than four 
weeks) may not tolerate surgery.  
Local control of the metastatic lesion can be achieved by either wide 
resection and reconstruction or intralesional curettage with an adjuvant modality as 
this can improve survival compared to those patients with no surgical intervention 
done, with no survival difference (Weber et al., 2006), Unique factors in our setting 
compared to western communities are that many patients before coming to see 
professionals they tend to use deferent types of  alternative treatment, causing 
 20 
delayed presentation. So by doing this study, we hope to be able to evaluate whether 
this factors will influence the outcome of surgical treatment.(Katagiri, 2014). 
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CHAPTER 2 
      LITERATURE REVIEW 
 
2.1  Characteristic of bone metastasis  
The bone of patients with breast cancer is the first site to be affected in 26% 
of cases and 74% of all patients. As the lesions may be osteolytic, osteoblastic or 
mixed; the five-year survival rate for metastatic breast cancer is 22%. Lung cancer 
'Small-cell' carcinoma and adenocarcinoma frequently had metastasis to the skeleton; 
the lesions are usually osteolytic and only in 25% of the cases are osteoblastic (table 
2:1). Lung cancer has with bone involvement  prognosis not promising as the five-
year survival rate only 2%, the 'non-small-cell' type of bronchogenic carcinoma has a 
five-year survival rate reach to 10% after surgery. Furthermore, the prognosis after 
irradiation is 3% to 9%, and 14% after local irradiation plus chemotherapy. However, 
the 'small-cell' type has a worse prognosis, and it is usually treated by chemotherapy 
with or without radiotherapy with a disease-free survival at two years in only 17% of 
cases (Fairchild, 2014). 
 
Spine lesions are the most common site of bone involvement in patients with 
prostate cancer, followed by femur, pelvis, ribs, sternum, skull, and humerus. 
Symptomatic lumbar and cervical metastases involvement develop in 27% and 6% of 
prostate patients. The lesions are usually osteoblastic (84%) or mixed (12%) and 
rarely osteolytic (4%). pathological fractures are rarely seen in patients with spine 
metastasis due to prostate cancer that is referred to Osteoblastic nature of the lesions. 
Moreover, a high potential for union after fixation and  five-year survival rate for 
metastatic prostate cancer is around  33%(Sarahrudi et al., 2009). 
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Kidney cancer has the potential to develop lung metastasis followed by 
skeletal and brain. In cases of bone lesions, the cortex may disappear without 
periosteal reaction and soft-tissue expansion, with high risk of pathological fracture 
in around (50%) of cases that especially in spine involvement as well as long bones. 
Metastases from renal cancer originally known to have intense vascularity because of 
that selective embolization which is indicated preoperatively to reduce bleeding 
during operation especially for lesions located in the spine, pelvis or shoulder girdle, 
in which five-year survival rate after resection of a solitary metastasis 35% is 
expected. On the other hand, multiple lesions and palliative surgery indicated the 
median survival of about 12 months. 
In thyroid cancer, patients develop bone metastasis in 4%, pulmonary 
metastases in 9% of cases, bone metastases are usually osteolytic and 
hypervascularised. Solitary lesion may be observed in 30%, rate of survival at five 
years is 44%. However, the expected survival is less than one year for anaplastic 
tumors(Sim, 1988). 
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Table ‎2:1 Incidence and Prognosis of Bone Metastases due to variation of 
primary tumor  
 
 
  
 
Incidence of advanced disease Median survival in months 5-yr survival 
Myeloma 95-100% 20 10% 
Breast 65-75% 24 20% 
Prostate 65-75% 40 25% 
Lung 30-40% <6 <5% 
Kidney 20-25% 6 10% 
Thyroid 60% 48 40% 
Melanoma 14-45% <6 <5% 
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2.2  Pathogenesis of bone metastasis 
It’s‎ not‎ uncommon‎ for‎ cancer‎ patients to have bone metastasis; that is 
expected because of the favorable microenvironment of the bone matrix and its 
abundance of blood supply. Bone metastasis begins when primary tumor cells detach 
from their place of origin by forming new blood vessels and invade the vasculature. 
These tumor cells then form aggregates and eventually adhere to the vascular 
endothelial cells of distant capillaries of the bone. Subsequently, the cells that escape 
the circulation invades the marrow stroma, and ultimately adhere to the endosteal 
surface of the bone and proliferate. A variety of factors have been implicated in the 
metastatic process, including proteolytic enzymes, cell adhesion molecules (CAMs), 
and growth factors. Proteolytic enzymes are necessary for tumor cells to detach from 
their primary site, invade the surrounding soft tissue, enter and exit the vasculature, 
and degrade the bone matrix. Metalloproteinases (MMPs) have been implicated in 
bone resorption and tumor progression. CAMs, such as integrins, play a critical role 
in tumor invasion, metastasis, and proliferation Tumor cells secrete parathyroid 
hormone-related protein (PTHrP) and IL-6, which are powerful mediators of 
osteoclast activation higher levels of expression are associated with sites of bone 
metastases (Powell et al., 1991), participate in osteolysis by stimulating the 
production of receptor activator of nuclear factor-kB ligand (RANKL) by osteoblasts 
and stromal cells. The  RANKL binds to its receptor (Pugh et al.) on osteoclast 
progenitors, leading to the differentiation of the progenitors into mature osteoclasts 
and initiation of bone resorption. 
Simply metastasis of tumor cells to bone requires a complex cascade of 
actions involving detachment from the primary tumor site, invasion of the 
vasculature, migration and adherence to distant capillaries of the bone, extravasation, 
